Inogen, Inc. Q3 2025 Earnings Recap

INGN Q3 2025 November 6, 2025

Get alerts when INGN reports next quarter

Inogen delivered another quarter of mid-single-digit revenue growth, reaching over $92 million, buoyed by robust domestic and international demand for portable oxygen concentrators (POCs) while also demonstrating progress toward profitability.

Earnings Per Share Beat

$-0.20 vs $-0.22 est.

+9.1% surprise

Revenue Beat

92390000 vs 88600000 est.

+4.3% surprise

Market Reaction

1-Day -4.87%

5-Day -5.41%

30-Day -5.95%

See INGN alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved 15% year-over-year unit growth in POCs, contributing to seven consecutive quarters of mid-single-digit revenue growth.
International B2B sales surged 19% year-over-year, emphasizing the success of global market expansion efforts.
Adjusted EBITDA reached $2.3 million, marking the third consecutive quarter of profitability, with revised full-year expectations now approximating $2 million.
Launch of Voxi 5, a new stationary oxygen concentrator, is gaining traction, enhancing product offerings in the oxygen therapy market.
Ongoing R&D investment and a focused strategy on international markets position Inogen for sustained growth in the underpenetrated COPD space.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit INGN on AllInvestView.